engleski

PREVALENCE OF HUMAN LEUKOCYTE ANTIGEN HLA-B*57:01 IN HIV-1 INFECTED PATIENTS IN CROATIA

The presence of human leukocyte antigen HLA- B*57:01 is associated with abacavir hypersensitivity. Despite its efficacy, approximately 5% of individuals who receive abacavir develop an immune-mediated hypersensitivity reaction (HSR). Therefore it is important to determine the carrier frequency prior to choosing optimal therapy for HIV-1 infected patients, since B*57:01 prevalence varies among different populations. Screening for HLA-B*57:01 allele was introduced in 2009 as a part of routine care for all patients ; newly-diagnosed patients entering clinical care, treatment naive patients diagnosed with HIV-infection prior to January 2009 and treatment- experienced patients. The aim of this study was to determine the prevalence of the HLA-B*57:01 allele in the HIV- positive patients receiving clinical care in Reference center in Croatia, from January 2017 until September 2020. Blood samples from 374 HIV- infected patients (353 males, 20 females, 1 transgender, median age 37 years, range 18-85 years) in Croatia were analyzed. Presence of HLA-B*57:01 allele was determined by Real- Time amplification test for the detection of HLA-B using the HLA B*57:01 Real-Time kit (Sacace Biotechnologies, Como, Italy). Fifteen of 374 HIVinfected patients (4%) were positive for the presence of HLA-B*57:01 allele in the period from January 2017 until September 2020. In conclusion, the prevalence of HLA-B*57:01 allele in Croatian HIV- infected patients is slightly lower than the prevalence in Caucasian HIV-infected patients worldwide (5.6%).

HLA-B*57:01 status; abacavir; HIV-infected patients

nije evidentirano